Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity

Authors:

Abstract
Objective: Our objective was to model the potential cost‐effectiveness of tirzepatide as an alternative to lifestyle modification (LSM) for the management of obesity and overweight.Methods: An individual‐level discrete event simulation was implemented in Microsoft Excel linking short‐term outcomes from the SURMOUNT‐1 trial to key obesity‐related complications to estimate costs and health benefits of tirzepatide (5‐mg, 10‐mg, or 15‐mg doses) and LSM over a lifetime time horizon. Treatment‐related changes in cardiometabolic factors were modeled using data from SURMOUNT‐1; the relationship between patient status and risk of obesity complications was obtained from published literature. Modeled complications included cardiovascular events, onset of type 2 diabetes, cancer, osteoarthritis, and sleep apnea. The model simulated 1000 adult patients with overweight or obesity over their lifetimes, applying a 3% annual discount rate to cost and health outcomes. Only direct medical costs were considered.Results: Tirzepatide 5, 10, and 15 mg provided 0.54, 0.55, and 0.61 additional quality‐adjusted life years (QALYs) and additional costs of $79,288, $70,453, and $75,839 versus LSM, yielding incremental cost‐effectiveness ratios of $146,331, $127,644, and $125,053 per QALY gained, respectively.Conclusions: The model predicted that all doses of tirzepatide represent cost‐effective alternatives to LSM for management of overweight and obesity at a willingness‐to‐pay threshold of $150,000 per QALY.
Funding Information
  • Eli Lilly and Company

This publication has 30 references indexed in Scilit: